A Gene Expression Profile Test for the Differential Diagnosis of Ovarian Versus Endometrial Cancers

We have developed a gene expression profile test (Pathwork Tissue of Origin Endometrial Test) that distinguishes primary epithelial ovarian and endometrial cancers in formalin-fixed, paraffin-embedded (FFPE) specimens using a 316–gene classification model. The test was validated in a blinded study using a pre-specified algorithm and microarray files for 75 metastatic, poorly differentiated or undifferentiated specimens with a known ovarian or endometrial cancer diagnosis. Measures of test performance include a 94.7% overall agreement with the known diagnosis, an area under the ROC curve (AUC) of 0.997 and a diagnostic odds ratio (DOR) of 406. Ovarian cancers (n=30) gave an agreement of 96.7% with the known diagnosis while endometrial cancers (n=45) gave an agreement of 93.3%. In a precision study, concordance in test results was 100%. Reproducibility in test results between three laboratories was 94.3%. The Tissue of Origin Endometrial Test can aid in resolving important differential diagnostic questions in gynecologic oncology.

[1]  L. Monti,et al.  Molecular signature induced by RNASET2, a tumor antagonizing gene, in ovarian cancer cells , 2011, Oncotarget.

[2]  D. Katsaros,et al.  Netrin-1 overexpression is predictive of ovarian malignancies , 2011, Oncotarget.

[3]  Eric T. Wang,et al.  Molecular classification of thyroid nodules using high-dimensionality genomic data. , 2010, The Journal of clinical endocrinology and metabolism.

[4]  R. Fodde,et al.  Wnt/Β-Catenin and Sex Hormone Signaling In Endometrial Homeostasis and Cancer , 2010, Oncotarget.

[5]  Bradley P. Carlin,et al.  Bayesian Adaptive Methods for Clinical Trials , 2010 .

[6]  L. Tafe,et al.  Endometrial and ovarian carcinomas with undifferentiated components: clinically aggressive and frequently underrecognized neoplasms , 2010, Modern Pathology.

[7]  A. Verbeek,et al.  The Association between Primary Endometrioid Carcinoma of the Ovary and Synchronous Malignancy of the Endometrium , 2009, Obstetrics and gynecology international.

[8]  Yin-hua Yu,et al.  HOXA10 is Overexpressed in Human Ovarian Clear Cell Adenocarcinoma and Correlates With Poor Survival , 2009, International Journal of Gynecologic Cancer.

[9]  R. Soslow,et al.  Application of immunohistochemistry to gynecologic pathology. , 2009, Archives of pathology & laboratory medicine.

[10]  I. Jacobs,et al.  HOXA11 DNA methylation—A novel prognostic biomarker in ovarian cancer , 2008, International journal of cancer.

[11]  C. Perou,et al.  RNA expression analysis of formalin-fixed paraffin-embedded tumors , 2007, Laboratory Investigation.

[12]  A. Hummer,et al.  Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis , 2006, Modern Pathology.

[13]  A. Scorilas,et al.  Human Kallikrein 8 Protein Is a Favorable Prognostic Marker in Ovarian Cancer , 2006, Clinical Cancer Research.

[14]  Yinhua Yu,et al.  Potential markers that complement expression of CA125 in epithelial ovarian cancer. , 2005, Gynecologic oncology.

[15]  K A Baggerly,et al.  New tumor markers: CA125 and beyond , 2005, International Journal of Gynecologic Cancer.

[16]  Adam Kowalczyk,et al.  An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. , 2005, Cancer research.

[17]  Wenjun Cheng,et al.  Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract , 2005, Nature Medicine.

[18]  John Quackenbush,et al.  Multiple-laboratory comparison of microarray platforms , 2005, Nature Methods.

[19]  E. Diamandis,et al.  Human Kallikrein 6: A New Potential Serum Biomarker for Uterine Serous Papillary Cancer , 2005, Clinical Cancer Research.

[20]  Kathleen F. Kerr,et al.  Standardizing global gene expression analysis between laboratories and across platforms , 2005, Nature Methods.

[21]  A. Whittemore,et al.  Histologic types of epithelial ovarian cancer: have they different risk factors? , 2005, Gynecologic oncology.

[22]  Kenneth H Buetow,et al.  Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  K. Chang,et al.  Discordant genetic changes in ovarian and endometrial endometrioid carcinomas: a potential pitfall in molecular diagnosis , 2004, International Journal of Gynecologic Cancer.

[24]  D. Schriger.  Bayesian Approaches to Clinical Trials and Health-Care Evaluation, D.J. Spiegelhalter, K.R. Abrams, J.P. Myles. John Wiley & Sons (2004), 406 pages, $85.00 ISBN 0-47149975-7 , 2004 .

[25]  W. McCluggage,et al.  WT‐1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma , 2004, Histopathology.

[26]  D. Spiegelhalter,et al.  Disease Mapping With WinBUGS and MLwiN, Bayesian Approaches to Clinical Trials and Health Care Evaluation , 2004 .

[27]  P. Bossuyt,et al.  The diagnostic odds ratio: a single indicator of test performance. , 2003, Journal of clinical epidemiology.

[28]  M. Zweig,et al.  Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. , 1993, Clinical chemistry.

[29]  C. la Vecchia,et al.  Epidemiologic pathology of ovarian cancer from the Vaud Cancer Registry, Switzerland. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  M. Mazur,et al.  Metastases to the female genital tract: Analysis of 325 cases , 1984, Cancer.

[31]  Jacob Cohen.  A Coefficient of Agreement for Nominal Scales , 1960 .

[32]  L. Buturovic,et al.  Validation and reproducibility of a microarray-based gene expression test for tumor identification in formalin-fixed, paraffin-embedded specimens. , 2011, The Journal of molecular diagnostics : JMD.

[33]  Liu Ji-hon.  The NCCN clinical practice guidelines in oncology for uterine neoplasms 2011 , 2011 .

[34]  W. Isaacs,et al.  The Prostate 69 : 214 ^ 218 ( 2009 ) Genome-Wide ExpressionAnalysis of Recently ProcessedFormalin-FixedParaffinEmbeddedHuman ProstateTissues , 2008 .

[35]  I. Yang,et al.  Multi-platform, multi-site, microarray-based human tumor classification. , 2004, The American journal of pathology.

[36]  A. Gown,et al.  Immunohistochemical analysis of gynecologic tumors. , 2001, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[37]  Thomas D. Wu,et al.  Bmc Medical Genomics Microarray Analysis of Rna Extracted from Formalin-fixed, Paraffin-embedded and Matched Fresh-frozen Ovarian Adenocarcinomas , 2022 .